Underscoring this association between striatal gene regulation and behavior, our present results demonstrate that a dose of vilazodone that suppressed the development of L-DOPA-induced dyskinesia inhibited this L-DOPA-induced expression of 5-HT1B, presumably in dMSNs [29], while not inhibiting the lesion-induced increase in 5-HT1B, presumably in iMSNs. The gene discussed is HTR1B; the disease is Dyskinesia.